Psychiatry · AntipsychoticRegulatory Approvalcommercialmid-term

FDA grants AP status for Quetiapine Fumarate ANDA206252 by Accord Healthcare

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/28/2026, 6:31:38 PM

Assessment confidence: 60% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Accord Healthcare's ANDA for Quetiapine Fumarate signifies a potential shift in the competitive landscape for antipsychotic medications. This could lead to pricing pressures and market share erosion for existing branded products and other generics. Regulatory context from FDA (FDA AP — QUETIAPINE FUMARATE (SUPPL)) supports the near-term read. Assessment grounded in 19 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential market entry of Accord's generic Quetiapine and its effects on pricing and market share. The strongest clinical anchor is The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer. In Psychiatry · Antipsychotic, 7 regulatory and 3 competitive items passed relevance filtering for Quetiapine.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for TZIELD (Teplizumab) Supplement (Humanexa Signals) — mechanism alignment (io ). Secondary pressure from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy. This approval status may allow Accord Healthcare to enter the market with a generic version of Quetiapine, impacting existing branded products and other generics.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — QUETIAPINE FUMARATE (SUPPL) (FDA). Entity match (quetiapine); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. While the approval status is a positive development for Accord, it also indicates a need for existing players to ensure compliance and readiness for competitive market dynamics.

Key Risks

Elevated medium regulatory exposure for Quetiapine could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The entry of Accord's generic Quetiapine could significantly impact revenue streams for current market players, potentially leading to a decrease in prices and market share for established brands.
Upside for Quetiapine may improve if Perceptions, knowledge, and access to the HPV vaccine among parents and healthcare providers in South Quito, Ecuador in 2025: A qualitative study. (PubMed) delivers favorable follow-through.
Upside for Quetiapine may improve if Trends in ritodrine prescriptions among pregnant women in Japan: a nationwide descriptive analysis of an administrative hospital database from 2015 to 2024. (PubMed) delivers favorable follow-through.
Portfolio teams should assess the potential market entry of Accord's generic Quetiapine and its effects on pricing and market share.

What Would Change This Assessment

This becomes more urgent if Monitor the timeline for market launch and any subsequent competitive responses from other manufacturers.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — QUETIAPINE FUMARATE (SUPPL)
FDAhigh relevance
Entity match (quetiapine); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — TENOFOVIR ALAFENAMIDE FUMARATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
Transparency data: Medicines and Healthcare products Regulatory Agency Privacy Notice
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
Corporate report: Medicines and Healthcare Products Regulatory Agency Annual Report and Accounts 2025 to 2026
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
Policy paper: Medicines and Healthcare products Regulatory Agency (MHRA) economic growth goals
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Menstrual Status, Anesthetic Consumption, and PONV
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Physical Restraints in Intensive Care Unit Patients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Longitudinal Investigation of the Endocrine and Neurobiologic Events Accompanying Puberty
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Grants Priority Review for TZIELD (Teplizumab) Supplement
Humanexa Signalshigh relevance
Mechanism alignment (IO )
FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Approval for Dexmedetomidine Hydrochloride by Baxter Healthcare
Humanexa Signalsmedium relevance
Moderate corpus alignment

Perceptions, knowledge, and access to the HPV vaccine among parents and healthcare providers in South Quito, Ecuador in 2025: A qualitative study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trends in ritodrine prescriptions among pregnant women in Japan: a nationwide descriptive analysis of an administrative hospital database from 2015 to 2024.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Cost-effectiveness of multitarget stool DNA testing for colorectal cancer screening in Chinese primary healthcare settings: a modelling study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Quetiapine

Commercial impact

high

The entry of Accord's generic Quetiapine could significantly impact revenue streams for current market players, potentially leading to a decrease in prices and market share for established brands.

Regulatory impact

medium

While the approval status is a positive development for Accord, it also indicates a need for existing players to ensure compliance and readiness for competitive market dynamics.

What to watch

Monitor the timeline for market launch and any subsequent competitive responses from other manufacturers.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.